Landing pages/general information

• NIH COVID-19 Portfolio Tool
• Open Mike explainer on COVID-19 Funding and Funding Opportunities
• NIH COVID-19 overview presentation (PowerPoint)
• NIH COVID-19 overview talking points (Word doc)
• NIH COVID-19 landing page
• NIH Grants and Funding COVID-19 landing page

Funding opportunities

• NOT-DE-20-022 NIDCR Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR
• NOT-NS-20-051 NINDS Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System
• PAR-20-178 NIAID Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)
• PAR-20-177 NIAID Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)
• PA-20-072 AHRQ Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research (PCOR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement –  Clinical Trial Optional)
• PA-20-070 AHRQ Competitive Revision Supplements to Existing AHRQ Health Service Research (HSR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement –  Clinical Trial Optional)
• NOT-RM-20-015 Common Fund Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
• NOT-TR-20-028 NCATS Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs
• NOT-OD-20-097 Multiple NIH Organizations Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences
• NOT-ES-20-020 NIEHS Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)
• NOT-EB-20-007 NIBIB Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)
• NOT-GM-20-027 NIGMS Notice of Special Interest (NOSI): Urgent Competitive Revisions to Accelerate Research on the Development of Predictive Models of the Spread of SARS-CoV-2 and Outcomes of Potential Public Health Interventions on COVID-19
• NOT-ES-20-017 NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)
• NOT-EB-20-006 NIBIB Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)
• NOT-EB-20-007 NIBIB Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)
• NOT-EB-20-008 NIBIB Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)
• NOT-DK-20-020 NIDDK Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) Related to HIV Comorbidities, Coinfections, and Complications within NIDDK’s Mission
• NOT-MD-20-019 NIA, NIMH and NIMHD Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities
• NOT-MH-20-047 NIMH Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus
• NOT-TR-20-016 NCATS Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus
• NOT-CA-20-043 NCI Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)
• NOT-TR-20-017 NCATS Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus
• NOT-DC-20-004 NIDCD Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)
  • NOT-DC-20-006 Notice of Eligibility Change for NIDCD Urgent Competitive Revisions and Administrative Supplements for Research on COVID-19
• NOT-DK-20-018 NIDDK Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK
  • NOT-DK-20-026 NIDDK Notice of Additional Activity Code Accepted for “NOT-DK-20-018, Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK”
• NOT-CA-20-048 NCI Notice of National Cancer Institute (NCI) Participation in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”
• NOT-AG-20-022 NIA and NIMH Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
  • NOT-AG-20-031 Frequently Asked Questions for NOT-AG-20-022 Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
• NOT-HG-20-030 NHGRI Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
• NOT-TR-20-012 NCATS Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)
• NOT-AI-20-031 NIAID Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
• NOT-HS-20-008 AHRQ Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19
• NOT-HS-20-007 AHRQ Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19
• NOT-GM-20-025 NIGMS Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2
• NOT-AI-20-034 NIAID Notice of Special Interest regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
• NOT-TR-20-011 NCATS Notice of Special Interest: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need
• NOT-DA-20-047 NIDA Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
• NOT-HL-20-757 NHLBI Notice of Special Interest: Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
  • NOT-HL-20-789 NHLBI Notice of Expiration of NOT-HL-20-757 “Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)”

Parent grants

• PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement –  Clinical Trial Optional)
• PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)

Policies and guidelines

• NOT-CA-20-054 NCI Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis
• Open Mike blog: Temporary, Emergency Situations Due to COVID-19 and Application Scores Received During Peer Review

• What happens if an institution has already submitted an application, and due to effects of COVID-19, some of the information needs to be revised?

• Open Mike blog: Cyber Safety & COVID-19

• Open Mike blog: Supporting Yourself and Your Trainees During the Coronavirus Pandemic – Online Workshops
• NOT-GM-20-026 NIGMS Guidance for Cost-Related Flexibilities Available to Support of Competitive Research (SCORE) Award Recipients Affected by COVID-19
• NOT-HL-20-759 NHLBI Announces Availability of Frequently Asked Questions (FAQs) for NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
• NOT-HS-20-010 AHRQ Flexibilities Available to AHRQ Recipients and Applicants Directly Impacted by the Novel Coronavirus (COVID-19) Due to Loss of Operations
• NOT-FD-20-019 FDA Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19
• NOT-OD-20-091 UPDATE: NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19)
• Open Mike Blog: Responding to Frequent Questions on Flexibilities Related to NIH Funding and COVID-19
  • Video FAQ with Mike Lauer, NIH Deputy Director for Extramural Research: Update on COVID-19 Flexibilities for the Research Community
• NOT-OD-20-088 OLAW flexibilities for activities of Institutional Animal Care and Use Committees affected by COVID-19
• NOT-OD-20-087 NIH guidance on its clinical trials and human subjects studies affected by COVID-19
• FDA guidance on conducting clinical trials of medical products during COVID-19 outbreak
• NOT-OD-20-082 NIH’s late application policy for applications affected by COVID-19
• NOT-OD-20-083 COVID-19 FAQs for proposal submission and award management
• NOT-OD-20-086 NIH flexibilities to applicants and recipients of federal funding affected by COVID-19
• FAQs about the flexibilities the NIH is allowing
• Travel and meeting guidance for NIH gatherings
• OLAW webinar recording and transcript on contingency planning for animal care

Image above: This scanning electron microscope image shows SARS-CoV-2 (orange)—also known as 2019-nCoV, the virus that causes COVID-19—isolated from a patient in the U.S., emerging from the surface of cells (green) cultured in the lab. Credit: NIAID-RML